With a median follow-up time of 39.6 months, median overall survival was 13.0, 12.7, and 16.3 months for arms 1, 2, and 3, respectively. During induction chemotherapy, grade 3/4 granulocytopenia ...

In a phase II trial, 99 patients were randomly assigned to bevacizumab 7.5 (n = 32) or 15 mg/kg (n = 35) plus carboplatin (area under the curve = 6) and paclitaxel (200 mg/m 2) every 3 weeks or ...

Doctors are contending with low supplies and unfilled orders of generic chemotherapy infusions that are central to the treatment of a long list of cancers.

CHICAGO (Reuters) - Abraxis Bioscience Inc said its cancer drug Abraxane outperformed the generic drug Taxol in patients with non-small cell lung cancer, without requiring patients to take steroids or ...